Dr. Padda links obesity, heart disease and nerve damage in new patient guides
Dr. Gurpreet Singh Padda has released new patient and physician guides based on the Obesity Medicine Association’s 2026 statement on obesity and cardiovascular disease. The guides argue that the same inflamed fat that drives heart risk can also damage nerves, making numb feet and chronic pain possible early warning signs.
Why it matters: - The guides frame obesity as a whole-body disease that can injure both the heart and the nervous system, not just raise body weight. - Dr. Gurpreet Singh Padda says the approach could help identify risk earlier than standard checkups that focus mainly on cholesterol and blood sugar. - The guides point to waist size, fasting insulin, inflammation and body composition as measures that may reveal risk before obvious disease develops.
What happened: - Dr. Gurpreet Singh Padda, MD, MBA, MHP, who directs Measura and Regenerve in St. Louis, published patient and physician guides built on the Obesity Medicine Association’s 2026 Clinical Practice Statement on obesity and cardiovascular disease. - The Obesity Medicine Association statement, published in Obesity Pillars, describes two routes from excess fat to the heart: fat mass disease and sick fat disease, also called adiposopathy. - The guides also make the case that inflamed fat can injure nerves, and that the feet may be the first place symptoms show up.
The details: - Fat mass disease refers to the physical burden of excess tissue, which increases what the heart must supply and is tied to heart failure and sleep apnea. - Sick fat disease refers to fat tissue that no longer functions normally and sends immune and hormone signals that drive type 2 diabetes, high blood pressure, abnormal lipids and clotting. - Fat around the heart can inflame the heart from the outside in. - The statement’s management conclusion is to treat obesity first, rather than only chasing downstream risk factors. - Dr. Padda said, “A scale weighs the load. It cannot see the chemistry.” - High-sensitivity C-reactive protein, or hs-CRP, is a blood test used to gauge low-grade inflammation and heart risk. - hs-CRP under 1 mg/L is associated with lower risk, 1 to 3 mg/L with average risk and above 3 mg/L with higher risk. - The CANTOS trial enrolled 10,061 people who had already had a heart attack and still had hs-CRP of 2 mg/L or more. - In CANTOS, blocking one inflammatory signal did not lower cholesterol, but the 150 mg dose reduced repeat heart attacks, strokes and cardiovascular deaths by 15% versus placebo over a median 3.7 years. - By 2017 to 2018, under 7% of U.S. adults met optimal cardiometabolic health criteria in NHANES. - In an NHANES study of 7,116 U.S. adults age 40 and older, people with diabetes who had lost feeling in their feet had a 66% higher risk of cardiovascular death than people with diabetes whose feet tested normal. - In a German study of 513 adults age 62 to 81, every 5 cm of extra waist circumference raised the odds of neuropathy by 22%, with the same pattern in people with and without diabetes. - Dr. Padda said, “The standard diabetes test, hemoglobin A1C, underestimates the risk of diabetes by 75 percent.” - The guides connect inflammation that affects artery walls with sensitivity in small pain fibers and the dorsal root ganglion. - In the UK Biobank, chronic widespread pain among 475,171 adults carried a 48% higher adjusted risk of heart attack, stroke, heart failure or cardiovascular death. - The share of cardiovascular disease attributable to chronic pain was 8.6%, compared with 7.3% attributable to diabetes. - Dr. Padda said, “A burning or numb foot is less a foot problem than an early report on the whole system, the heart included.” - Measura’s guides focus on what standard cholesterol panels and risk calculators may miss, including waist and body composition, fasting insulin, hs-CRP and fat around the heart. - Regenerve’s guides explain how inflammation and excess weight can affect nerves. - In the SELECT trial, 17,604 adults with existing cardiovascular disease, a BMI of 27 or more and no diabetes received weekly semaglutide or placebo. - Heart attack, stroke or cardiovascular death occurred in 6.5% of the semaglutide group and 8.0% of the placebo group, a 20% relative reduction. - GLP-1 medicines may be part of the solution for selected patients after a full evaluation, with follow-up using the same measurements. - Dr. Padda said, “Treat the fat first, measure whether it is working, and the heart and the nerves both get the benefit.” - The patient guides are available at Measura’s obesity and heart disease guide and Regenerve’s neuropathy and heart disease guide.
Between the lines: - The release argues for a wider view of cardiometabolic care, where nerve symptoms can serve as an early warning sign of heart risk. - The emphasis on measuring inflammation, insulin and body composition suggests a more targeted approach than relying on weight alone or on standard lab panels. - The repeated focus on “measure first, then treat” positions obesity treatment as the starting point for reducing both cardiovascular and neuropathy risk.
What’s next: - Measura and Regenerve are steering patients toward guides that translate the 2026 obesity-cardiovascular statement into practical screening steps. - The message from the release is that clinicians may need to look earlier and broader at patients with numb feet, chronic pain, central obesity or elevated inflammation. - The clinics say treatment decisions should be followed by repeat measurement to see whether risk is falling.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Today in Healthcare
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.